NCT04115111View on ClinicalTrials.gov

Diadem to Investigate the Activity and Safety of Durvalumab

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

May 16, 2019

Study Completion Date

May 16, 2019

Conditions
Pleura Mesothelioma
Interventions
DRUG

Durvalumab

Durvalumab in monotherapy as second line treatment

Trial Locations (1)

20133

San Gerardo Hospital, Monza

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT04115111 - Diadem to Investigate the Activity and Safety of Durvalumab | Biotech Hunter | Biotech Hunter